Compare Amphastar Pharmaceuticals Inc (AMPH) vs Byrna Technologies Inc (BYRN) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

BYRN trades at $4.45, up 2.06% today, but faces bearish technical signals and recent earnings challenges. The company reported a Q2 2026 loss of $0.44 per share, missing estimates, with revenue declining 42.5% year-over-year. Despite a 71.4% analyst buy rating, negative net income margin and cash flow concerns highlight operational headwinds. Recent management appointments aim to revitalize marketing and retail growth.

Outlook remains cautious due to weak sales trends and profitability issues, though strategic hires and acquisitions could support a turnaround. Key risks include sustained revenue declines and competitive pressures. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.